Cabaletta Bio, Inc. 8-K

What Happened

Cabaletta Bio, Inc. announced an underwritten registered direct offering of 51,725,000 shares of common stock priced at $2.90 per share under an Underwriting Agreement dated May 4, 2026 with TD Securities (USA) LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co. The purchase price to the underwriters is $2.726 per share (a 6.0% discount). The offering is expected to close on May 5, 2026, and the company estimates net proceeds of approximately $141 million after underwriting discounts, commissions and expenses. The shares are being issued under a previously declared shelf registration (Form S-3); a prospectus supplement was filed May 4, 2026.

Key Details

• 51,725,000 shares offered at $2.90 per share; underwriter purchase price $2.726 (6.0% discount).
• Estimated net proceeds to Cabaletta: approximately $141 million. Expected close: May 5, 2026.
• Preliminary cash and cash equivalents as of March 31, 2026: approximately $117 million (subject to completion of Q1 financial results).
• Stated use of proceeds: fund expanded clinical development of rese-cel (including ongoing myositis registrational study and potential additional registrational studies), advance manufacturing readiness for commercial launch, and general corporate purposes.

Why It Matters

The financing materially increases Cabaletta’s liquidity, which the company says — combined with existing cash — should fund operations and planned development activities into mid‑2027. Retail investors should note the March 31, 2026 cash figure is preliminary and the company has not yet filed its formal quarterly results, which could change reported balances. The filing also includes forward‑looking statements about use of proceeds and runway, which are subject to risks and uncertainties disclosed in Cabaletta’s SEC filings.